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index. The higher the accuracy of the predictive system, the
higher the optimization of HCV treatment and the development
of new antiviral drugs make it imperative.
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Letters to the EditorTo the Editor:
We read with great interest the recent meta-analysis by Deltenre
et al. [1]. Authors included 14 studies involving 2732 HCV-posi-
tive patients and showed that insulin-resistance (IR) has an
evident negative association with the possibility of achieving a
sustained virological response (SVR) to Peg-Interferon and
ribavirin, in particular in patients with genotype 1 infection. As
discussed, some important limitations do not allow an indepen-
dent association of IR with treatment failure to be highlighted.
Other predictive factors, genetic and non-genetic, could be
behind this association such as IL-28 polymorphism, ﬁbrosis,
age, viremia, presence of steatosis and other clinical variables
associated with the metabolic syndrome. Hence, a real cause-
effect relation is still an open question, and a sort of ‘‘dose effect’’
of IR on SVR has never been exhaustively explored. We believe
that investigations aimed at solving these issues are a priority
area of research in order to optimize the management of HCV
patients. In accordance with the results by Walsh et al. [2],
authors argued the overexpression of suppressor of cytokine
signaling (SOCS-3) induced by HCV as one of the mechanisms
evoked to explain the association of the metabolic syndrome with
non-response to antiviral therapy. However, they consider this
observation as never conﬁrmed by other studies. Nevertheless,
we wish to point out that Huang et al. [3] and our personal data
[4] have conﬁrmed the overexpression of SOCS-3 in the liver of
non-responders to antiviral therapy. Moreover, in vitro data by
our group suggested that this is dependent on the genotype, giv-
ing an indirect clue that, if an interference of HCV with insulin
signaling exists, it could be mainly due to genotype 1 infection
[5], but the debate is still open [6]. Deltenre et al. also stated that
the HOMA-IR index measured prior to antiviral therapy could be
useful to implement a potential combined score at basal evalua-
tion to predict treatment response. We totally agree with this
statement but we probably need to take a step before moving for-
ward. The individual value of HOMA-IR index has been largely
discussed [7]. Exploring the possibility of a dose effect of IR on
SVR is probably the ﬁrst step to take as a reliable cut-off to deﬁne
the presence of IR by HOMA does not exist, neither the reproduc-
ibility of a speciﬁc cut-off in patients with or without clinical
features of metabolic syndrome has ever been explored. All these
aspects, presently, do not allow taking a step forward in terms of
further predicting SVR in HCV patients by using the HOMA-IR472 Journal of Hepatology 2012 vol. 57 j 467–477
